Showing 34,701 - 34,720 results of 63,199 for search '(( 01 ((1 decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (mean decrease)) ))', query time: 1.26s Refine Results
  1. 34701
  2. 34702
  3. 34703
  4. 34704
  5. 34705
  6. 34706
  7. 34707
  8. 34708
  9. 34709

    The cell viability of C35 siRNA1-treated breast ductal carcinoma cells after C35 gene was overexpressed. by Wen Che (4405504)

    Published 2017
    “…The decreased viability in C35 siRNA1-treated BT-474 cells was restored after C35 was overexpressed at 48 h. ** indicates that <i>p</i> < 0.01 as compared with the control group. ## indicates that <i>p</i> < 0.01 as compared with siRNA1 group alone.…”
  10. 34710

    Supplementary Material for: Impact of the national action plan for antimicrobial resistance on antibiotic use for mastitis using a Japanese nationwide database by Konishi T. (14239904)

    Published 2023
    “…The trend of broad-spectrum antibiotics administration significantly changed at the publication (-2,6% [95% confidence interval, -3.9% to -1.3%], P<0.001) and the administration decreased after the publication (1.9% annual decrease, Ptrend<0.001). …”
  11. 34711
  12. 34712
  13. 34713
  14. 34714

    DataSheet_1_The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass.docx by Tuo Pan (9264234)

    Published 2023
    “…</p>Results<p>In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01).…”
  15. 34715

    DataSheet_1_The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass.docx by Tuo Pan (9264234)

    Published 2023
    “…</p>Results<p>In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01).…”
  16. 34716
  17. 34717
  18. 34718
  19. 34719
  20. 34720